1. Home
  2. STOK vs CYD Comparison

STOK vs CYD Comparison

Compare STOK & CYD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STOK
  • CYD
  • Stock Information
  • Founded
  • STOK 2014
  • CYD 1951
  • Country
  • STOK United States
  • CYD Singapore
  • Employees
  • STOK N/A
  • CYD N/A
  • Industry
  • STOK Biotechnology: Pharmaceutical Preparations
  • CYD Industrial Machinery/Components
  • Sector
  • STOK Health Care
  • CYD Industrials
  • Exchange
  • STOK Nasdaq
  • CYD Nasdaq
  • Market Cap
  • STOK 740.9M
  • CYD 609.7M
  • IPO Year
  • STOK 2019
  • CYD 1994
  • Fundamental
  • Price
  • STOK $12.85
  • CYD $22.37
  • Analyst Decision
  • STOK Strong Buy
  • CYD
  • Analyst Count
  • STOK 5
  • CYD 0
  • Target Price
  • STOK $27.75
  • CYD N/A
  • AVG Volume (30 Days)
  • STOK 763.5K
  • CYD 192.1K
  • Earning Date
  • STOK 08-06-2025
  • CYD 08-08-2025
  • Dividend Yield
  • STOK N/A
  • CYD 1.73%
  • EPS Growth
  • STOK N/A
  • CYD 17.49
  • EPS
  • STOK 0.88
  • CYD 1.12
  • Revenue
  • STOK $190,908,000.00
  • CYD $2,621,360,849.00
  • Revenue This Year
  • STOK $378.84
  • CYD $6.43
  • Revenue Next Year
  • STOK N/A
  • CYD $11.20
  • P/E Ratio
  • STOK $14.68
  • CYD $20.82
  • Revenue Growth
  • STOK 2333.81
  • CYD 6.03
  • 52 Week Low
  • STOK $5.35
  • CYD $8.61
  • 52 Week High
  • STOK $16.15
  • CYD $26.10
  • Technical
  • Relative Strength Index (RSI)
  • STOK 55.41
  • CYD 46.24
  • Support Level
  • STOK $12.25
  • CYD $23.00
  • Resistance Level
  • STOK $13.12
  • CYD $25.65
  • Average True Range (ATR)
  • STOK 0.82
  • CYD 1.19
  • MACD
  • STOK -0.06
  • CYD -0.42
  • Stochastic Oscillator
  • STOK 35.70
  • CYD 25.16

About STOK Stoke Therapeutics Inc.

Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.

About CYD China Yuchai International Limited

China Yuchai International Ltd is a Bermuda holding company that is a subsidiary of Singapore-based Hong Leong Asia. China Yuchai International primarily operates through its majority-owned subsidiary Guangxi Yuchai Machinery Company, a China-based company that manufactures, assembles, and distributes diesel engines for various vehicles including trucks, buses, and cars, as well as construction and agricultural, marine, and power-generation equipment. It generates the majority of its sales from the Chinese market.

Share on Social Networks: